The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,614.00
Bid: 2,620.00
Ask: 2,622.00
Change: -22.00 (-0.83%)
Spread: 2.00 (0.076%)
Open: 2,640.00
High: 2,644.00
Low: 2,614.00
Prev. Close: 2,636.00
CCH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post 2022 AGM Shareholder Engagement

20 Dec 2022 10:16

RNS Number : 3308K
Coca-Cola HBC AG
20 December 2022
 

Coca-Cola HBC AG

Post 2022 AGM Shareholder Engagement - Update Statement

 

Zug, Switzerland - 20 December 2022 - In accordance with Provision 4 of the UK Corporate Governance Code, Coca-Cola HBC AG ("Coca-Cola HBC" or the "Company") is providing an update to the statement made on 21 June 2022 in relation to the voting outcomes of Resolution 7 and Resolution 9 at its Annual General Meeting ("AGM") which were advisory votes to approve the Company's UK Remuneration Report and Swiss Remuneration Report respectively, as well as Resolution 4.3 in relation to the re-election of Charlotte J. Boyle, Chair of the Remuneration Committee (the "Resolutions").

 

The Board of Directors understands the sensitivities around the issue of executive renumeration and it had consulted with its largest shareholders in the months prior to the AGM.

 

At the AGM, shareholders representing approximately 67% of the votes cast voted in favour of Resolution 7 and 9 and shareholders representing approximately 78% of the votes cast voted in favour of Resolution 4.3. Following the AGM, the Company and the Chair of the Remuneration Committee has continued its engagement with shareholders and their proxy advisors on remuneration issues, in particular to understand the reasons why certain shareholders were unable to support these Resolutions.

 

The Company is grateful to those shareholders that took the time to express their views and understands that shareholders' concerns were primarily connected to the adjustment of targets contained in the Company's incentive arrangements, in particular the original targets relating to the 2019 Performance Share Plan awards. The shareholder sentiment regarding the adjustments to the 2019 awards was also reflected in the voting outcome for the Chair of the Remuneration Committee. The Remuneration Committee sought to ensure that incentive arrangements continued to provide stretch in alignment with their original intent, and included downward adjustments, while adapting for the impact of COVID-19. The wider workforce experience was taken into account prior to taking any decisions on executive remuneration. Salary increases were given across the group at all levels and bonus pay outs were above target for the vast majority. In reviewing the 2019 Performance Share Plan awards, the Remuneration Committee believes and continues to believe, that the adjustments made were necessary to retain and incentivise the broader management team, in addition to the executive leadership and CEO. It is these individuals that were directly responsible for navigating the Company through the COVID-19 turbulence and delivering the strong financial performance seen in recovery. 

 

The Company would like to thank all the shareholders that have taken part in the engagement processes, and for the feedback provided. The Company will continue its constructive dialogue with shareholders and will seek to incorporate this feedback into future remuneration decisions.

 

In accordance with the UK Corporate Governance Code, a further update will be provided in the Company's 2022 annual report and accounts published in 2023.

Enquiries

Coca‑Cola HBC Group

Investors and Analysts:

Joanna Kennedy

Head of Investor Relations

Tel: +44 7802 427505

 joanna.kennedy@cchellenic.com

Jemima Benstead

Investor Relations Manager

Tel: +44 7740 535130

jemima.benstead@cchellenic.com

Marios Matar

Investor Relations Manager

Tel: +30 697 444 3335

marios.matar@cchellenic.com

Media:

Sonia Bastian

Head of Communications

Tel: +41 7946 88054

 sonia.bastian@cchellenic.com

 

About Coca‑Cola HBC

Coca-Cola HBC is a growth-focused consumer packaged goods business and strategic bottling partner of The Coca-Cola Company. We create value for all our stakeholders by supporting the socio-economic development of the communities in which we operate and we believe building a more positive environmental impact is integral to our future growth. Together, we and our customers serve 715 million consumers across a broad geographic footprint of 29 countries on three continents. Our portfolio is one of the strongest, broadest and most flexible in the beverage industry, offering consumer-leading beverage brands in the sparkling, juice, water, sport, energy, plant-based, ready-to-drink tea, coffee, adult sparkling and premium spirits categories. These beverages include Coca-Cola, Coca-Cola Zero, Schweppes, Kinley, Costa, Valser, Römerquelle, Fanta, Sprite, Powerade, FuzeTea, Dobry, Cappy, Monster and Adez. We foster an open and inclusive work environment amongst our 33,000 employees and we are ranked among the top sustainability performers in ESG benchmarks such as the Dow Jones Sustainability Indices, CDP, MSCI ESG and FTSE4Good.

 

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE:CCH) and is listed on the Athens Exchange (ATHEX:EEE). For more information, please visit https://www.coca-colahellenic.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKKBDKBDDPBB
Date   Source Headline
3rd May 20245:25 pmRNSTransaction in Own Shares
3rd May 202412:46 pmRNSDirector/PDMR Shareholding
3rd May 202412:38 pmRNSDirector/PDMR Shareholding
2nd May 20245:41 pmRNSTransaction in Own Shares
2nd May 202412:40 pmRNSAthens Exchange trading date of ordinary shares
1st May 20245:47 pmRNSTransaction in Own Shares
1st May 202410:09 amRNSBlock listing Interim Review
1st May 20249:10 amRNSIssue of equity and total voting rights
30th Apr 20247:00 amRNSStrong start; reiterating 2024 guidance
19th Apr 20249:20 amRNSNotice of AGM
18th Apr 20244:21 pmRNSDirector/PDMR Shareholding
5th Apr 20242:17 pmRNSNotice of Results
2nd Apr 202411:12 amRNSIssue of equity and total voting rights
28th Mar 20245:55 pmRNSDirector/PDMR Shareholding
28th Mar 20245:47 pmRNSDirector/PDMR Shareholding
28th Mar 20245:42 pmRNSDirector/PDMR Shareholding
28th Mar 20245:26 pmRNSTransaction in Own Shares
27th Mar 20245:23 pmRNSTransaction in Own Shares
26th Mar 20245:05 pmRNSTransaction in Own Shares
26th Mar 20249:09 amRNSDirector/PDMR Shareholding
25th Mar 20245:10 pmRNSTransaction in Own Shares
22nd Mar 20245:27 pmRNSTransaction in Own Shares - Replacement
22nd Mar 20245:05 pmRNSTransaction in Own Shares
21st Mar 20245:40 pmRNSTransaction in Own Shares
20th Mar 20245:33 pmRNSTransaction in Own Shares
19th Mar 20245:20 pmRNSTransaction in Own Shares
19th Mar 20241:19 pmRNSDirector/PDMR Shareholding
18th Mar 20245:20 pmRNSTransaction in Own Shares
15th Mar 20246:25 pmRNSTransaction in Own Shares
15th Mar 20245:58 pmRNSAnnual Financial Report
14th Mar 20245:30 pmRNSTransaction in Own Shares
14th Mar 20243:04 pmRNSDirector/PDMR Shareholding
14th Mar 20242:56 pmRNSDirector/PDMR Shareholding
13th Mar 20245:20 pmRNSTransaction in Own Shares
12th Mar 20245:15 pmRNSTransaction in Own Shares
11th Mar 20245:50 pmRNSTransaction in Own Shares
8th Mar 20245:45 pmRNSTransaction in Own Shares
7th Mar 20245:20 pmRNSTransaction in Own Shares
6th Mar 20245:10 pmRNSTransaction in Own Shares
5th Mar 20245:15 pmRNSTransaction in Own Shares
4th Mar 20245:55 pmRNSTransaction in Own Shares
1st Mar 20245:15 pmRNSTransaction in Own Shares
1st Mar 20249:25 amRNSIssue of Equity and total voting rights
29th Feb 20245:25 pmRNSTransaction in Own Shares
29th Feb 20243:10 pmRNSDirector/PDMR Shareholding
29th Feb 20243:00 pmRNSDirector/PDMR Shareholding
29th Feb 20242:53 pmRNSDirector/PDMR Shareholding
28th Feb 20245:25 pmRNSTransaction in Own Shares
27th Feb 20245:35 pmRNSTransaction in Own Shares
26th Feb 20245:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.